Bowman-Birk inhibitor concentrate suppresses experimental autoimmune neuritis via shifting macrophages from M1 to M2 subtype

Immunology Letters

Volumn 171, Issue , 2016, Pages 15-25

  Jin, Tao ^a   Yu, Hong ^a,b   Wang, Dan ^a,b   Zhang, Hongliang ^a,b   Zhang, Bo ^a,b   Quezada, Hernan Concha ^c   Zhu, Jie ^a,b   Zhu, Wei ^a  

^a JILIN UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bowman Birk inhibitor concentrate; Experimental autoimmune neuritis; Guillain Barr syndrome; M1 M2 cells; Macrophage

Indexed keywords

ARGINASE 1; BOWMAN BIRK INHIBITOR; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 4; MANNOSE RECEPTOR; MYELIN PROTEIN; PHOSPHATE BUFFERED SALINE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CYTOKINE; PLANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE NEURITIS; GUILLAIN BARRE SYNDROME; IMMUNOREGULATION; INOCULATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MONONUCLEAR CELL; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; T LYMPHOCYTE; TREATMENT OUTCOME; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; DRUG EFFECTS; GUILLAIN-BARRE SYNDROME; HUMAN; IMMUNOLOGY; LEWIS RAT; LYMPHOCYTE ACTIVATION; METABOLISM; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; SOYBEAN; TH1 TH2 BALANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; GUILLAIN-BARRE SYNDROME; HUMANS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MALE; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PLANT PROTEINS; RATS; RATS, INBRED LEW; SOYBEANS; TH1-TH2 BALANCE; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

EID: 84955615320     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2016.01.004     Document Type: Article

References (40)

1. Adelmann M., Linington C. Molecular mimicry and the autoimmune response to the peripheral nerve myelin PO glycoprotein. Neurochem. Res. 1992, 17:887-891.
2. Arbogast S., Smith J., Matuszczak Y., Hardin B.J., Moylan J.S., Smith J.D., Ware J., Kennedy A.R., Reid M.B. Bowman-Birk inhibitor concentrate prevents atrophy, weakness, and oxidative stress in soleus muscle of hindlimb-unloaded mice. J. Appl. Physiol. 2007, 102:956-964.
3. Armstrong W.B., Kennedy A.R., Wan X.S., Atiba J., McLaren C.E., Meyskens F.L. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol. Biomarkers Prev. 2000, 9:43-47.
4. Benoit M., Desnues B., Mege J.-L. Macrophage polarization in bacterial infections. J. Immunol. 2008, 181:3733-3739.
5. Bosurgi L., Manfredi A.A., Rovere-Querini P. Macrophages in injured skeletal muscle: a perpetuum mobile causing and limiting fibrosis, prompting or restricting resolution and regeneration. Front. Immunol. 2011, 2.
6. Chan W., White P.D. Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series) 2000, 99-110. Oxford University Press, USA.
7. Dai H., Ciric B., Zhang G.-X., Rostami A. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor. J. Neuroimmunol. 2012, 245:1-7.
8. Deng B., Wehling-Henricks M., Villalta S.A., Wang Y., Tidball J.G. IL-10 triggers changes in macrophage phenotype that promote muscle growth and regeneration. J. Immunol. 2012, 189:3669-3680.
9. Gran B., Tabibzadeh N., Martin A., Ventura E., Ware J., Zhang G., Parr J., Kennedy A., Rostami A. The protease inhibitor, Bowman-Birk inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis. Multiple Sclerosis 2006, 12:688-697.
10. Harlan D.M., Hengartner H., Huang M.L., Kang Y.-H., Abe R., Moreadith R.W., Pircher H., Gray G., Ohashi P.S., Freeman G.J. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. Proc. Natl. Acad. Sci. 1994, 91:3137-3141.
11. Kennedy A.R. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am. J. Clin. Nutr. 1998, 68:1406S-1412S.
12. Kennedy A.R., Beazer-Barclay Y., Kinzler K.W., Newberne P.M. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res. 1996, 56:679-682.
13. Kennedy A.R., Wan X.S. Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells. Prostate 2002, 50:125-133.
14. Kennedy A.R., Ware J.H., Carlton W., Davis J.G. Suppression of the later stages of radiation-induced carcinogenesis by antioxidant dietary formulations. Radiat. Res. 2011, 176:62-70.
15. Kieseier B.C., Hartung H.-P. Therapeutic strategies in the Guillain-Barre syndrome. Semin. Neurol. 2003, 159-168.
16. Korn T., Toyka K., Hartung H.-P., Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain 2001, 124:1791-1802.
17. Kou P.M., Babensee J.E. Macrophage and dendritic cell phenotypic diversity in the context of biomaterials. J. Biomed. Mater. Res. Part A 2011, 96:239-260.
18. Lichtenstein G.R., Deren J.J., Katz S., Lewis J.D., Kennedy A.R., Ware J.H. Bowman-Birk Inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig. Dis. Sci. 2008, 53:175-180.
19. Lin L.L., Mick R., Ware J., Metz J., Lustig R., Vapiwala N., Rengan R., Kennedy A.R. Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate. Oncol. Lett. 2014, 7:1151-1158.
20. Liu G., Ma H., Qiu L., Li L., Cao Y., Ma J., Zhao Y. Phenotypic and functional switch of macrophages induced by regulatory CD4+ CD25+ T cells in mice. Immunol. Cell Biol. 2011, 89:130-142.
21. Lu M.-O., Zhu J. The role of cytokines in Guillain-Barré syndrome. J. Neurol. 2011, 258:533-548.
22. Malkowicz S.B., McKenna W.G., Vaughn D.J., Wan X.S., Propert K.J., Rockwell K., Marks S.H., Wein A.J., Kennedy A.R. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 2001, 48:16-28.
23. Mikita J., Dubourdieu-Cassagno N., Deloire M.S., Vekris A., Biran M., Raffard G., Brochet B., Canron M.-H., Franconi J.-M., Boiziau C. Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Multiple Sclerosis J. 2011, 17:2-15.
24. Pan W., Kastin A.J. Changing the chemokine gradient: CINC1 crosses the blood-brain barrier. J. Neuroimmunol. 2001, 115:64-70.
25. Rostami A., Gregorian S.K., Brown M.J., Pleasure D.E. Induction of severe experimental autoimmune neuritis with a synthetic peptide corresponding to the 53-78 amino acid sequence of the myelin P2 protein. J. Neuroimmunol. 1990, 30:145-151.
26. Safavi F., Rostami A. Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases. Exp. Mol. Pathol. 2012, 93:428-433.
27. Shin T., Ahn M., Matsumoto Y. Mechanism of experimental autoimmune encephalomyelitis in Lewis rats: recent insights from macrophages. Anat. Cell Biol. 2012, 45:141-148.
28. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
29. Touil T., Ciric B., Ventura E., Shindler K.S., Gran B., Rostami A. Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis. J. Neurol. Sci. 2008, 271:191-202.
30. van den Berg B., Walgaard C., Drenthen J., Fokke C., Jacobs B.C., van Doorn P.A. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat. Rev. Neurol. 2014, 10:469-482.
31. Ware J.H., Wan X.S., Newberne P., Kennedy A.R. Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis. Digest. Dis. Sci. 1999, 44:986-990.
32. Zhang H.-L., Azimullah S., Zheng X.-Y., Wang X.-K., Amir N., Mensah-Brown E.P., Al Shamsi M., Shahin A., Press R., Zhu J. IFN-γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response. J. Neuroimmunol. 2012, 246:18-26.
33. Zhang H.-L., Hassan M.Y., Zheng X.-Y., Azimullah S., Quezada H.C., Amir N., Elwasila M., Mix E., Adem A., Zhu J. Attenuated EAN in TNF-α deficient mice is associated with an altered balance of M1/M2 macrophages. PLoS One 2012, 7:e38157.
34. Zhang H.-L., Mao X.-J., Zhang X.-M., Li H.-F., Zheng X.-Y., Adem A., Mix E., Zhu J. APOE ε3 attenuates experimental autoimmune neuritis by modulating T cell, macrophage and Schwann cell functions. Exp. Neurol. 2011, 230:197-206.
35. Zhu J., Bai X., Hedlund G., Björk J., Bakhiet M., Van Der Meide P., Link H. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin. Exp. Immunol. 1999, 115:56-63.
36. Zhu J., Mix E., Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barre syndrome. J. Neuroimmunol. 1998, 84:40-52.
37. Zhu J., Zou L.-P., Zhu S.-W., Mix E., Shi F.-D., Wang H.-B., Volkmann I., Winblad B., Schalling M., Ljunggren H.-G. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade enhances incidence and severity of experimental autoimmune neuritis in resistant mice. J. Neuroimmunol. 2001, 115:111-117.
38. Zhu W., Zhang K., Mix E., Wang X., Adem A., Zhu J. Differential susceptibility to experimental autoimmune neuritis in Lewis rat strains is associated with T-cell immunity to myelin antigens. J. Neurosci. Res. 2011, 89:448-456.
39. Zhu Y., Ljunggren H.-G., Mix E., Li H.-L., van der Meide P., Elhassan A.M., Winblad B., Zhu J. CD28-B7 costimulation: a critical role for initiation and development of experimental autoimmune neuritis in C57BL/6 mice. J. Neuroimmunol. 2001, 114:114-121.
40. Zou L.-P., Abbas N., Volkmann I., Nennesmo I., Levi M., Wahren B., Winblad B., Hedlund G., Zhu J. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 2002, 42:731-739.